Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Cardiothoracic Surgery
Published in: Journal of Cardiothoracic Surgery 1/2024

Open Access 01-12-2024 | Pleural Effusion | Research

Efficacy and safety of intrapleural perfusion with hyperthermic chemotherapy for malignant pleural effusion: a meta-analysis

Authors: Xue Pan, Zhichao Hou, Tangjuan Zhang, Zheng Ding, Fei Ye, Zhulin Wang, Chunyao Huang, Peng Wang, Xiangnan Li

Published in: Journal of Cardiothoracic Surgery | Issue 1/2024

Login to get access

Abstract

Objective

To evaluate the efficacy and safety of intrapleural perfusion with hyperthermic chemotherapy (IPHC) in treating malignant pleural effusion (MPE).

Methods

PubMed, Embase, Cochrane Library, Chinese National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), VIP Chinese Science and Technology Journal Full-text Database (VP-CSJFD), and Wanfang database were searched by computer from database establishment to January 17, 2024. Relevant randomized controlled articles with IPHC as the observational group and intrapleural perfusion chemotherapy (IPC) as the control group for MPE were included. Then, the methodological quality of the included articles was evaluated and statistically analyzed using Stata 16.0.

Results

Sixteen trials with 647 patients receiving IPHC and 661 patients receiving IPC were included. The meta-analysis found that MPE patients in the IPHC group had a more significant objective response rate [RR = 1.31, 95%CI (1.23, 1.38), P < 0.05] and life quality improvement rate [RR = 2.88, 95%CI (1.95, 4.24), P < 0.05] than those in the IPC group. IPHC and IPC for MPE patients had similar incidence rates of asthenia, thrombocytopenia, hepatic impairment, and leukopenia.

Conclusion

Compared with IPC, IPHC has a higher objective response rate without significantly increasing adverse reactions. Therefore, IPHC is effective and safe. However, this study is limited by the quality of the literature. Therefore, more high-quality, multi-center, large-sample, rigorously designed randomized controlled clinical studies are still needed for verification and evaluation.
Literature
1.
Thomas R, Francis R, Davies HE, Lee YC. Interventional therapies for malignant pleural effusions: the present and the future. Respirology. 2014;19(6):809–22.PubMedCrossRef
2.
Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM Stage groupings in the Forthcoming (Eighth) Edition of the TNM classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39–51.PubMedCrossRef
3.
4.
Ferreiro L, Suárez-Antelo J, Valdés L. Malignant pleural effusion management. Manejo Del derrame pleural maligno. Arch Bronconeumol (Engl Ed). 2021;57(1):7–8.PubMedCrossRef
5.
Walker-Renard PB, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions. Ann Intern Med. 1994;120(1):56–64.PubMedCrossRef
6.
Sakaguchi H, Ishida H, Nitanda H, Yamazaki N, Kaneko K, Kobayashi K. Pharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusion. Lung Cancer. 2017;104:70–4.PubMedCrossRef
7.
Chen WJ, Yuan SF, Yan QY, et al. Intrapleural chemo- and hyperthermotherapies for malignant pleural effusion: a randomized prospective study. Cancer Invest. 2012;30(2):126–30.PubMedCrossRef
8.
Tan C, Sedrakyan A, Browne J, Swift S, Treasure T. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg. 2006;29(5):829–38.PubMedCrossRef
9.
Neragi-Miandoab S. Malignant pleural effusion, current and evolving approaches for its diagnosis and management. Lung Cancer. 2006;54(1):1–9.PubMedCrossRef
10.
Musani AI. Treatment options for malignant pleural effusion. Curr Opin Pulm Med. 2009;15(4):380–7.PubMedCrossRef
11.
Wallner KE, DeGregorio MW, Li GC. Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug. Cancer Res. 1986;46(12 Pt 1):6242–5.PubMed
12.
Hettinga JV, Lemstra W, Konings AW, Kampinga HH. Cisplatin sensitivity and thermochemosensitisation in thermotolerant cDDP-sensitive and -resistant cell lines. Br J Cancer. 1995;71(3):498–504.PubMedPubMedCentralCrossRef
13.
Cao Y, Zhang Q, Huang Z, et al. Better effect of intrapleural perfusion with hyperthermic chemotherapy by video-assisted thoracoscopic surgery for malignant pleural effusion treatment compared to normothermic chemoperfusion of the pleural cavity. Cancer Med. 2022;11(2):348–57.PubMedCrossRef
14.
Liu Y, Wan L, Qu Z, et al. Effect of continuous hyperthermic perfusion chemotherapy on vascular endothelial growth factor and immune function in elderly patients with malignant pleural effusion. Chin J Gerontol. 2016;36(16):3986–7.
15.
Liu Y, Wan L, Gao J, et al. Effect of continuous hyperthermic perfusion chemotherapy on tumor markers in elderly patients with malignant pleural effusion. Chin J Gerontol. 2020;40(2):304–7.
16.
Liang M, Du J, Jiang D, et al. Observation on the therapeutic effect of continuous circulating thoracic hyperthermic perfusion on malignant pleural effusion. Chin J Pulmonary Dis (Electronic Edition). 2016;9(4):415–7.
17.
Zhao C, Wang Y, Li J. Efficacy of kanglaite hyperthermic perfusion in the treatment of malignant pleural effusion. Shanxi Med J. 2015;44(18):2101–2.
18.
Xu X, Zhang W, Wen A, et al. Observation on Kanglaite Hyperthermic Intrapleural infusion in the treatment of advanced malignant pleural effusion. Chin J Clin Oncol Rehab. 2011;18(1):88–90.
19.
Wu C, Li J, Lin K, et al. Clinical efficacy of intrapleural hyperthermic perfusion of Nedaplatin in the treatment of malignant pleural effusion of lung cancer.  Chin J Cancer Prev Treat. 2017;9(6):486–8.
20.
Wang C, Wang M. Comparative clinical efficacy of intrapleural perfusion chemotherapy and intrapleural circulatory hyperthermic perfusion chemotherapy in non-small cell lung cancer with concomitant pleural effusion. Henan Med Res. 2020;29(10):1786–7.
21.
Duan F, Qi X, Wan J. Clinical observation on hyperthermic perfusion chemotherapy in the treatment of malignant pleural effusion. J Practical Cancer. 2003;18(6):635–7.
22.
Lu Z, Lu G, Huang J, et al. Clinical observation on hyperthermic perfusion chemotherapy in the treatment of malignant pleural effusion. China Med Herald. 2013;10(12):163–5.
23.
Li Z, Zhang L, Li L. Clinical observation on 30 cases of malignant pleural effusion treated by hyperthermic perfusion chemotherapy. Mod Oncol. 2010;18(8):1565–7.
24.
Guorong Y, Jie M, Sun L. Clinical observation on intrapleural infusion of warm chemotherapy in the treatment of malignant pleural effusion. Occupation Health. 2006;22(15):1217–8.
25.
Liu L, Lu Y, Shao W. Comparison of efficacy of intrapleural infusion chemotherapy and hyperthermic intrapleural circulation chemotherapy in the treatment of pleural effusion in patients with cellular lung cancer. Mod Oncol. 2019;27(11):1895–9.
26.
Cao Y, Zhang Q, Huang Z, Chai Z, Liu J, Wang J, Sun Z, Zhao T, Wang G, Chen G, Han Y, Li Q, Hong X. Better effect of intrapleural perfusion with hyperthermic chemotherapy by video-assisted thoracoscopic surgery for malignant pleural effusion treatment compared to normothermic chemoperfusion of the pleural cavity. Cancer Med. 2022;11(2):348–57.PubMedCrossRef
27.
Cao D, Zhang J, Cheng Y. Therapeutic effect of thoracic circulatory hyperthermic perfusion chemotherapy on patients with non-small cell lung cancer combined with pleural effusion. Progress Cancer. 2023;21(1):49–52.
28.
Cao Y, Xu H, Chen Y, et al. Efficacy of thoracoscopic hyperthermic perfusion chemotherapy in the treatment of malignant pleural effusion and its impact on the tumor inflammatory microenvironment. Med Theory Pract. 2022;35(14):2356–8, 2362.
29.
Chen WJ, Yuan SF, Yan QY, Xiong JP, Wang SM, Zheng WE, Zhang W, Sun HY, Chen H, Wu LL. Intrapleural chemo- and hyperthermotherapies for malignant pleural effusion: a randomized prospective study. Cancer Invest. 2012;30(2):126–30.PubMedCrossRef
30.
31.
Zhan Z, Wang X, Yu J, et al. Intraperitoneal infusion of recombinant human endostatin improves prognosis in gastric cancer ascites. Future Oncol. 2022;18(10):1259–71.PubMedCrossRef
32.
33.
Kim HC, Kim E, Jeong SW, et al. Magnetic nanoparticleconjugated polymeric micelles for combined hyperthermia and chemotherapy. Nanoscale. 2015;7:16470–80.PubMedCrossRef
34.
35.
Speit G, Schütz P. Hyperthermia-induced genotoxic effects in human A549 cells. Mutat Res. 2013;747–748:1–5.PubMedCrossRef
36.
Zhao P, Jiang H, Su D, et al. Inhibition of cell proliferation by mild hyperthermia at 43˚C with Paris Saponin I in the lung adenocarcinoma cell line PC-9. Mol Med Rep. 2015;11:327–32.PubMedCrossRef
37.
Wust P, Hildebrandt B, Sreenivasa G, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol. 2002;3:487–97.PubMedCrossRef
38.
Saga T, Sakahara H, Nakamoto Y, et al. Enhancement of the therapeutic outcome of radio-immunotherapy by combination with whole-body mild hyperthermia. Eur J Cancer. 2001;37:1429–34.PubMedCrossRef
39.
Foo CT, Paterson A, Duckworth A, Herre J. Intrapleural hyaluronidase in viscous malignant mesothelioma pleural effusion. Chest. 2021;160(6):e609–11.PubMedCrossRef
40.
Murthy V, Katzman D, Sterman DH. Intrapleural immunotherapy: an update on emerging treatment strategies for pleural malignancy. Clin Respir J. 2019;13(5):272–9.PubMedCrossRef
41.
Chen KH, Yang YS, Chen R et al. Effects of intracavitary administration of elemene combined with nedaplatin on malignant pleural effusion. Bull Cancer. 2021;S0007-4551(21)00360-X. [Published online ahead of print, 2021 Oct 14].
42.
Chen L, Zhu X, Li D, Cai X. Effect of thoracic hyperthermic perfusion with recombinant human endostatin plus nedaplatin in treating pleural effusion in patients with advanced non-small cell lung cancer. J BUON. 2020;25(6):2643–9.PubMed
43.
Ma X, Yao Y, Yuan D, et al. Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice. PLoS One. 2012;7(12):e53449.PubMedPubMedCentralCrossRef
Metadata
Title
Efficacy and safety of intrapleural perfusion with hyperthermic chemotherapy for malignant pleural effusion: a meta-analysis
Authors
Xue Pan
Zhichao Hou
Tangjuan Zhang
Zheng Ding
Fei Ye
Zhulin Wang
Chunyao Huang
Peng Wang
Xiangnan Li
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Journal of Cardiothoracic Surgery / Issue 1/2024
Electronic ISSN: 1749-8090
DOI
https://doi.org/10.1186/s13019-024-02751-6

Other articles of this Issue 1/2024

Journal of Cardiothoracic Surgery 1/2024 Go to the issue

Research

Surgical strategy for intravenous leiomyomatosis spreading from uterine to the right atrium presenting with recurrent syncope

Case Report

Gastric and cardiac inflammatory myofibroblastic tumor: an extremely rare case

Research

Zero-leak prediction during major lung resection aiming for minimal chest drainage duration: a retrospective analysis

Review

Risk factors for postoperative delirium in patients with Stanford type A aortic dissection: a systematic review and meta-analysis

Review

Safety and efficacy of Cox‐Maze procedure for atrial fibrillation during mitral valve surgery: a meta-analysis of randomized controlled trials

Correspondence

When to anatomically excise a benign lung tumor-correspondence regarding the article: “large mesenchymal cystic and chondroid pulmonary hamartoma mimicking lung cancer: case report”